Pharma GCCs – What Used to Happen in Boston or Basel Now Happens in Bangalore

GCCs - Indian Pharma moves up the Value Chain - Sanofi, Amgen, Eli Lilly, J&J and others are investing billions in India’s new breed of Global Capability Centres

For decades, multinational pharma companies viewed India through a single lens — low-cost manufacturing and generic scale. Those days are gone. The India footprint has steadily climbed the value ladder: from contract development and manufacturing organisations (CDMOs) to clinical research organisations (CROs), then FDA-approved plants, and now Global Capability Centres (GCCs) that run on data, science and strategy.